Perennial Investment Advisors LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,720 shares of the medical research company's stock, valued at approximately $863,000.
A number of other institutional investors have also made changes to their positions in TMO. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $7,505,000. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $15,501,867,000. German American Bancorp Inc. bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $4,920,000. Hudson Value Partners LLC boosted its position in Thermo Fisher Scientific by 24.9% during the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock worth $8,349,000 after buying an additional 3,317 shares during the period. Finally, Clearstead Trust LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $3,779,000. 89.23% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
TMO has been the topic of a number of recent research reports. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target on the stock. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Jefferies Financial Group reissued a "buy" rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Finally, KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $619.41.
Get Our Latest Stock Report on TMO
Insiders Place Their Bets
In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company's stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock worth $44,122,820 in the last 90 days. Company insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Stock Up 1.0%
Thermo Fisher Scientific stock opened at $634.48 on Thursday. The company has a market capitalization of $234.60 billion, a PE ratio of 34.13, a PEG ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00. The firm's fifty day moving average is $552.22 and its 200 day moving average is $510.70. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the prior year, the company earned $4.28 earnings per share. The company's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Recommended Stories
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
